Evidence map›Paper›PMID 35637215›Full record

ArticleCell death & disease2022

Inhibiting multiple forms of cell death optimizes ganglion cells survival after retinal ischemia reperfusion injury.

Qiyu Qin, Naiji Yu, Yuxiang Gu, Weishaer Ke, Qi Zhang, Xin Liu, Kaijun Wang, Min Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 3 pooled it
15.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 3 syntheses or guidelines pooled it, 104 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Qiyu Qin *Eye Center, the Second Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, Zhejiang Province, China.
Naiji Yu *Eye Center, the Second Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, Zhejiang Province, China.
Yuxiang GuEye Center, the Second Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, Zhejiang Province, China.
Weishaer KeEye Center, the Second Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, Zhejiang Province, China.
Qi ZhangEye Center, the Second Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, Zhejiang Province, China.
Xin LiuEye Center, the Second Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, Zhejiang Province, China.
Kaijun WangEye Center, the Second Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, Zhejiang Province, China. ze_wkj@zju.edu.cn.
Min ChenEye Center, the Second Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, Zhejiang Province, China. chenmineye@zju.edu.cn.ORCID 0000-0003-0460-8403
Second Affiliated Hospital of Zhejiang University · CNZhejiang Technical Institute of Economics · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Progressive retinal ganglion cells (RGCs) death that triggered by retinal ischemia reperfusion (IR), leads to irreversible visual impairment and blindness, but our knowledge of post-IR neuronal death and related mechanisms is limited. In this study, we first demonstrated that apart from necroptosis, which occurs before apoptosis, ferroptosis, which is characterized by iron deposition and lipid peroxidation, is involved in the whole course of retinal IR in mice. Correspondingly, all three types of RGCs death were found in retina samples from human glaucoma donors. Further, inhibitors of apoptosis, necroptosis, and ferroptosis (z-VAD-FMK, Necrostatin-1, and Ferrostatin-1, respectively) all exhibited marked RGC protection against IR both in mice and primary cultured RGCs, with Ferrostatin-1 conferring the best therapeutic effect, suggesting ferroptosis plays a more prominent role in the process of RGC death. We also found that activated microglia, Müller cells, immune responses, and intracellular reactive oxygen species accumulation following IR were significantly mitigated after each inhibitor treatment, albeit to varying degrees. Moreover, Ferrostatin-1 in combination with z-VAD-FMK and Necrostatin-1 prevented IR-induced RGC death better than any inhibitor alone. These findings stand to advance our knowledge of the post-IR RGC death cascade and guide future therapy for RGC protection.

Indexed as

Reperfusion InjuryRetinal DiseasesAnimalsCell DeathMiceRetinaRetinal Ganglion Cells

Identifiers

PMID35637215
PMCPMC9151775
OpenAlexW4282048658

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.